Nirsevimab immunization's real-world effectiveness in preventing severe bronchiolitis: A test-negative case-control study.
Marta AgüeraAleix Soler-GarciaCarme AlejandreSara Moussalam-MerinoPere Sala-CastellvíGemma PonsDaniel Penela SánchezCarla González-GradoJudit Alsina-RosellCarme ClimentCristina EstevaClàudia FortunyMariona F de-SevillaJuan-José García-GarcíaPedro BrotonsAlbert BalaguerJosep EstradaIolanda Jordan-GarcíaCarmen Muñoz-AlmagroCristian LaunesPublished in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2024)
This study provides real-world evidence of the effectiveness of nirsevimab in preventing RSV-lower respiratory tract infection hospitalization and severe disease in infants during their first RSV season following a systematic immunization program. Immunized patients did not exhibit a higher rate of viral coinfections nor differences in clinical severity once admitted.